Differential Reponses of Hematopoietic Stem and Progenitor Cells to mTOR Inhibition

Abnormal activation of the mammalian target of rapamycin (mTOR) signaling pathway has been observed in a variety of human cancers. Therefore, targeting of the mTOR pathway is an attractive strategy for cancer treatment and several mTOR inhibitors, including AZD8055 (AZD), a novel dual mTORC1/2 inhib...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Aimin, Xiao, Xia, Zhao, Mingfeng, LaRue, Amanda C., Schulte, Bradley A., Wang, Gavin Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4499403/
https://www.ncbi.nlm.nih.gov/pubmed/26221145
http://dx.doi.org/10.1155/2015/561404

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4499403/
https://www.ncbi.nlm.nih.gov/pubmed/26221145
http://dx.doi.org/10.1155/2015/561404

Ejemplares similares